Patient Age, Tumor Risk Linked With Expectant Management in Prostate Cancer

Share this content:
Patient age and tumor risk may be more strongly associated with use of expectant management for veterans with low-risk prostate cancer.
Patient age and tumor risk may be more strongly associated with use of expectant management for veterans with low-risk prostate cancer.

Patient age and tumor risk may be more strongly associated with use of expectant management than patient comorbidity for veterans with low-risk prostate cancer, according to a study published in Cancer.1

Researchers examined veterans with prostate cancer in 2008 in order to determine the association between various factors and expectant management use.

They looked at documentation from an in-depth chart review and performed multivariable regression models to look at associations between expectant management and patient demographics, cancer severity, and facility characteristics.

The researchers found that expectant management use was more common in patients who were 75 years or older as well as those with low-risk tumors. They found no association between patient comorbidity and receipt of expectant management.

Additionally, they found that receipt of expectant management varied considerably among the individual facilities that were observed.

RELATED: Chemoimmunotherapy May Be Safe, Effective for Prostate Cancer

“Research determining the basis of this variation, with a focus on providers, will be critical to help optimize prostate cancer treatment for veterans,” the authors concluded.

Reference

  1. Filson CP, Shelton JB, Tan H, et al. Expectant management of veterans with early-stage prostate cancer [published online ahead of print November 5, 2015]. Cancer. doi: 10.1002/cncr.29785.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters